RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Clinical trials for RELAPSED OR REFRACTORY MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Early trial halted: testing combo therapy for Tough-to-Treat blood cancer
Disease control TerminatedThis study aimed to test the safety and effectiveness of adding a new drug called INCB001158 to an existing myeloma treatment (daratumumab) for people whose cancer has come back or stopped responding to other therapies. It involved 15 participants and compared the combination to …
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
Experimental cell therapy tested for Tough-to-Treat blood cancer
Disease control TerminatedThis study tested a type of immunotherapy called CAR-T for patients with multiple myeloma that had returned or stopped responding to other treatments. The goal was to see if this personalized cell therapy was safe and could help control the cancer. The trial was very small and en…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: NA • Sponsor: Guangzhou Bio-gene Technology Co., Ltd • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC